Loading...
XNAS
MRUS
Market cap3.06bUSD
May 02, Last price  
44.19USD
1D
-2.77%
1Q
7.94%
Jan 2017
109.33%
IPO
341.90%
Name

Merus NV

Chart & Performance

D1W1MN
P/E
—
P/S
84.61
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.54%
Rev. gr., 5y
3.02%
Revenues
36m
-17.78%
260,984944,8411,437,6922,859,57614,882,30935,973,46131,133,00029,943,00049,107,00041,586,00043,947,00036,133,000
Net income
-215m
L+38.97%
000000-55,151,000-85,513,000-66,816,000-131,194,000-154,939,000-215,326,000
CFO
-186m
L+30.68%
000000-63,048,000-79,901,000-59,627,000-149,899,000-142,207,000-185,835,000
Earnings
May 06, 2025

Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
URL
https://merus.nl/
IPO date
May 19, 2016
Employees
164
Domiciled in
NL
Incorporated in
NL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
36,133
-17.78%
43,947
5.68%
41,586
-15.32%
Cost of revenue
308,200
200,494
213,606
Unusual Expense (Income)
NOPBT
(272,067)
(156,547)
(172,020)
NOPBT Margin
Operating Taxes
8,151
3,192
959
Tax Rate
NOPAT
(280,218)
(159,739)
(172,979)
Net income
(215,326)
38.97%
(154,939)
18.10%
(131,194)
96.35%
Dividends
Dividend yield
Proceeds from repurchase of equity
457,476
225,945
57,740
BB yield
-16.94%
-15.92%
-8.31%
Debt
Debt current
1,704
1,674
1,684
Long-term debt
18,120
22,650
25,264
Deferred revenue
19,574
38,771
Other long-term liabilities
(8,208)
(3,365)
Net debt
(704,211)
(388,164)
(299,738)
Cash flow
Cash from operating activities
(185,835)
(142,207)
(149,899)
CAPEX
(1,667)
(3,982)
(7,639)
Cash from investing activities
(220,222)
(27,020)
2,802
Cash from financing activities
494,008
230,086
58,739
FCF
(299,902)
(158,396)
(190,537)
Balance
Cash
537,027
355,176
290,229
Long term investments
187,008
57,312
36,457
Excess cash
722,228
410,291
324,607
Stockholders' equity
6,957
(769,711)
(623,819)
Invested Capital
757,094
1,154,790
917,354
ROIC
ROCE
EV
Common stock shares outstanding
64,221
51,605
44,919
Price
42.05
52.91%
27.50
77.76%
15.47
-51.35%
Market cap
2,700,483
90.29%
1,419,150
104.22%
694,898
-43.44%
EV
1,996,272
1,030,986
395,160
EBITDA
(269,596)
(154,007)
(170,735)
EV/EBITDA
Interest
2,722
Interest/NOPBT